Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

Saved in:
Bibliographic Details
Published in:American journal of hematology 2018-10, Vol.93 (10), p.E342-E345
Main Authors: Racil, Zdenek, Koritakova, Eva, Sacha, Tomasz, Klamova, Hana, Belohlavkova, Petra, Faber, Edgar, Rea, Delphine, Malaskova, Ludmila, Prochazkova, Jirina, Zackova, Daniela, Voglova, Jaroslava, Wącław, Joanna, Cetkovsky, Petr, Zak, Pavel, Mayer, Jiri
Format: Article
Language:English
Subjects:
Anthropometry
Antineoplastic Agents - adverse effects
Dasatinib - adverse effects
Glucose Intolerance - chemically induced
Glucose Intolerance - physiopathology
Glucose metabolism
Hematology
Humans
Hyperinsulinism - chemically induced
Hyperinsulinism - physiopathology
Imatinib Mesylate - adverse effects
Insulin
Insulin - blood
Insulin Resistance
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Male
Prospective Studies
Protein Kinase Inhibitors - adverse effects
Pyrimidines - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.25232